STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA”, the “Company”), a leader in PCR-based DNA manufacturing for product authenticity and traceability solutions, announced today that it received a $1 million order to supply SigNature® T taggant for cotton in the upcoming 2019 – 2020 ginning season which begins in October. The Company’s SigNature T technology, paired with its genotyping and digital systems, will be used to tag, test and track the Pima cotton variety grown in the San Joaquin Valley, California that is sold under the PimaCott® brand nationwide and online by the largest home goods retailer in the U.S.
“We are pleased that the value of forensic traceability and genotyping for cotton continues to translate to recurring demand for tagged cotton across the home textile category,” said Dr. James A. Hayward, president and CEO of Applied DNA. “We believe the SigNature T platform, combined with our partner’s high standards in supply chain quality practices, assure them brand protection and label-claim compliance for retailers and consumers.”
The SigNature T system utilizes fully-automated DNA Transfer Systems in the “Industrial Internet of Things” design to ensure origin tagging process quality and as a basis for monitoring shipments, receipts and contract compliance. In addition to our Pima business, systems are installed in American Upland and Egyptian varietal cotton gins. While the SigNature T analysis confirms the traceability mark, a patented fiberTyping® analysis confirms cotton species from fiber to finished goods. Since 2014, and including the cotton tagged with this order, over 250 million pounds of cotton will have been tagged as the key to a total end-to-end traceability solution that is substantiated by forensic test data. Over 7,000 DNA tests have been conducted on cotton during the past five years.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and isolation of circulating tumor cells and the development of pre-clinical nucleic acid-based therapeutic drug candidates.
Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.
Common stock listed on NASDAQ under the symbol APDN, and warrants listed under the symbol APDNW.
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its ability to continue as a going concern, its history of net losses, limited financial resources, limited market acceptance, uncertainties relating to its ability to maintain its NASDAQ listing in light of delisting notices received and its recent hearing, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018, as amended and our subsequent quarterly reports on Form 10-Q filed on February 7, 2019, May 9, 2019 and August 13, 2019 and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.